The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Amgen; Atara Biotherapeutics; Bristol-Myers Squibb/Roche; CARGO Therapeutics; Celgene; CovACE Nanotechnology; crispr therapeutics; EUSA Pharma; Kite/Gilead; Novartis; WUGEN, Inc.
Research Funding - Amgen; Kite, a Gilead company
Phase 2 open label, multicenter study evaluating CRG-022, a CD22-directed autologous CAR T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after CD19-directed CAR T-cell therapy.
 
Armin Ghobadi
No Relationships to Disclose
 
Caron Alyce Jacobson
Honoraria - Abbvie; Abintus Bio; ADC Therapeutics; Appia Bio; AstraZeneca; Bristol-Myers Squibb; Caribou Biosciences; Celgene; Daiichi Sankyo/UCB Japan; ImmPACT-Bio; Ipsen; Janssen; Kite/Gilead; Miltenyi Biomedicine; MorphoSys; Novartis; Sana; Synthekine
Consulting or Advisory Role - Abbvie; Abintus Bio; ADC Therapeutics; Appia Bio; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo/UCB Japan; ImmPACT-Bio; Ipsen; Janssen; Kite/Gilead; Miltenyi Biomedicine; MorphoSys; Novartis; Sana; Synthekine
Research Funding - Kite, a Gilead company; Pfizer
 
Joseph McGuirk
Honoraria - AlloVir; Kite, a Gilead company; Magenta Therapeutics; Nektar; Sana Biotechnology
Consulting or Advisory Role - Allovir; crispr therapeutics; EcoR1 Capital; Juno Therapeutics; Kite, a Gilead company; Magenta Therapeutics
Speakers' Bureau - Kite/Gilead
Research Funding - AlloVir (Inst); Astellas Pharma (Inst); Bellicum Pharmaceuticals (Inst); Fresenius Biotech (Inst); Gamida Cell (Inst); Kite, a Gilead company (Inst); Novartis (Inst); Novartis (Inst); Pluristem Therapeutics (Inst)
Travel, Accommodations, Expenses - Kite, a Gilead company; SITC/ACCC; Syncopation Life Sciences
 
Nirali Shah
No Relationships to Disclose
 
John Rossi
Employment - CARGO Therapeutics
Leadership - CARGO Therapeutics
Stock and Other Ownership Interests - Amgen; CARGO Therapeutics; Gilead Sciences
Research Funding - CARGO Therapeutics
Travel, Accommodations, Expenses - CARGO Therapeutics
 
Tonia Jane Buchholz
Employment - CARGO Therapeutics
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene
 
Lizamarie Bachier-Rodriguez
Speakers' Bureau - Kite, a Gilead company
 
John H. Baird
Honoraria - Curio Science; Olson Research Group
Consulting or Advisory Role - Gerson Lehrman Group
Speakers' Bureau - Kite/Gilead
Research Funding - Genentech/Roche (Inst); Janssen Oncology (Inst); Kite/Gilead (Inst); Regeneron (Inst)
 
Catherine S. Diefenbach
Stock and Other Ownership Interests - Gilead Sciences; OverT Therapeutics
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Genmab; Janssen; Merck; MorphoSys; Regeneron; Seagen
Research Funding - Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); FATE Therapeutics (Inst); Genentech (Inst); Incyte (Inst); Janssen (Inst); LAM Therapeutics (Inst); MEI Pharma (Inst); MEI Pharma (Inst); Merck (Inst); Millennium (Inst); Roche/Genentech (Inst); Seagen (Inst); Trillium Therapeutics (Inst)
Expert Testimony - Jim Harmon
 
Umar Farooq
Honoraria - Caribou Biosciences; Kite, a Gilead company; Morphosys
Research Funding - Checkmate Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Kite, a Gilead company
 
Francisco J. Hernandez-Ilizaliturri
Consulting or Advisory Role - Abbvie; BeiGene; Epizyme; Kite/Gilead; Morphosys; Novartis; Pharmacyclics; Seagen
 
Iris Isufi
Consulting or Advisory Role - ADC Therapeutics; Bristol-Myers Squibb/Celgene; Caribou Biosciences; Genmab; Incyte; Janssen
Speakers' Bureau - Kite, a Gilead company
 
Krish Patel
Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene/Juno; Caribou Biosciences; Epizyme; Fate Therapeutics; Genentech; Kite, a Gilead company; Loxo/Lilly; Merck; Nurix; Pfizer; Pharmacyclics; Sana Biotechnology; Seagen; Xencor
Speakers' Bureau - AstraZeneca; Kite, a Gilead company
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); CARGO Therapeutics (Inst); Celgene (Inst); CRISPR Therapeutics (Inst); Fate Therapeutics (Inst); Janssen (Inst); Kite/Gilead (Inst); Loxo/Lilly (Inst); MEI Pharma (Inst); Merck (Inst); Nurix (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche/Genentech (Inst); Trillium Therapeutics (Inst); Xencor (Inst)
 
Sattva Swarup Neelapu
Stock and Other Ownership Interests - Longbow Immunotherapy
Honoraria - MJH Life Sciences; Peerview
Consulting or Advisory Role - Adicet Bio; Alimera Sciences; Astellas Pharma; Athenex; Bluebird Bio; Bristol-Myers Squibb; Caribou Biosciences; Chimagen Biosciences; Fosun Kite; Gilead Sciences; ImmunoACT; Incyte; Janssen medical Affairs; Kite, a Gilead company; Morphosys; Orna Therapeutics; Sana Biotechnology; Sellas Life Sciences; Takeda
Research Funding - Adicet Bio; Alimera Sciences; Bristol-Myers Squibb; Gilead Sciences; Kite, a Gilead company; Precision Biosciences
Patents, Royalties, Other Intellectual Property - Patents related to cellular therapy
 
Craig Steven Sauter
Consulting or Advisory Role - Celgene/Bristol-Myers Squibb; crispr therapeutics; Gilead Sciences; Ipsen; Kite, a Gilead company; MorphoSys; Ono Pharmaceutical; Syncopation Life Sciences
Research Funding - Affimed Therapeutics; CARGO; Nkarta; Sanofi
 
Jay Y. Spiegel
Consulting or Advisory Role - ImmPACT-Bio; Kite, a Gilead company
 
Michael Timothy Tees
No Relationships to Disclose
 
John Timmerman
Honoraria - Kite/Gilead
Consulting or Advisory Role - DAVA Oncology; Kite/Gilead; Oncovalent Therapeutics; Oncovalent Therapeutics
Research Funding - Bristol-Myers Squibb; Kite, a Gilead company; Merck
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Ginna Laport
Employment - CARGO Therapeutics; Genentech
Leadership - CARGO Therapeutics
Stock and Other Ownership Interests - CARGO Therapeutics; Genentech/Roche
 
Matthew Joshua Frank
Employment - Roche/Genentech (I)
Stock and Other Ownership Interests - Roche/Genentech (I)
Honoraria - Adaptive Biotechnologies; Kite/Gilead
Consulting or Advisory Role - CARGO Therapeutics; Kite, a Gilead company
Research Funding - Adaptive Biotechnologies; Allogene Therapeutics; CARGO Therapeutics; Kite, a Gilead company (Inst)
Travel, Accommodations, Expenses - CARGO Therapeutics; Kite, a Gilead company